                         SEQUENCE LISTING

<110>  TECHULON INC.
 
<120>  ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF PSEUDOMONAS AND 
       ACINETOBACTER INFECTIONS

<130>  3344.026PC01

<150>  US 62/954,133
<151>  2019-12-27

<160>  29    

<170>  PatentIn version 3.5

<210>  1
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  KFF peptide

<400>  1

Lys Phe Phe Lys Phe Phe Lys Phe Phe Lys 
1               5                   10  


<210>  2
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  RFF peptide


<220>
<221>  VARIANT
<222>  (1)..(10)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  2

Arg Phe Phe Arg Phe Phe Arg Phe Phe Arg 
1               5                   10  


<210>  3
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Magainin 2

<400>  3

Gly Ile Gly Lys Trp Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe 
1               5                   10                  15      


Val Gly Glu Ile Met Asn Ser 
            20              


<210>  4
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Transportin 10

<400>  4

Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu Lys Ala Leu Ala Ala Leu 
1               5                   10                  15      


Ala Lys Lys Ile Leu 
            20      


<210>  5
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic d,1-alpha-peptide

<400>  5

Lys Lys Leu Trp Leu Trp 
1               5       


<210>  6
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic d,1-alpha-peptide


<220>
<221>  VARIANT
<222>  (1)..(2)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  6

Arg Arg Lys Trp Leu Trp Leu Trp 
1               5               


<210>  7
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic d,1-alpha-peptide


<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  7

Lys Gln Arg Trp Leu Trp Leu Trp 
1               5               


<210>  8
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amphipathic peptide


<220>
<221>  VARIANT
<222>  (6)..(10)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  8

Leu Leu Ile Ile Leu Arg Arg Arg Ile Arg Lys Gln Ala His Ala His 
1               5                   10                  15      


Ser Lys 
        


<210>  9
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PENETRATIN 1 peptide


<220>
<221>  VARIANT
<222>  (1)..(11)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  9

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


<210>  10
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TAT peptide


<220>
<221>  variant
<222>  (2)..(10)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  10

Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Gln 
1               5                   10          


<210>  11
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Indolicidin


<220>
<221>  VARIANT
<222>  (11)..(13)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  11

Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg 
1               5                   10              


<210>  12
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCPP2


<220>
<221>  VARIANT
<222>  (10)..(12)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  12

Phe Lys Lys Ala Lys Lys Leu Phe Lys Arg Ile Arg 
1               5                   10          


<210>  13
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCPP3


<220>
<221>  Variant
<222>  (1)..(1)
<223>  Wherein Xaa is  -NH-(CH2)5C(O)-

<220>
<221>  Variant
<222>  (2)..(13)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  13

Xaa Arg Lys Leu Arg Arg Ile Lys Arg Phe Leu Leu Arg 
1               5                   10              


<210>  14
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCPP5


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Wherein Xaa is  -NH-(CH2)5C(O)-

<220>
<221>  VARIANT
<222>  (2)..(10)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  14

Xaa Arg Arg Trp Trp Arg Tyr Trp Arg Arg 
1               5                   10  


<210>  15
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCPP4


<220>
<221>  Variant
<222>  (1)..(12)
<223>  Wherein Xaa is  -NH-(CH2)5C(O)-

<220>
<221>  Variant
<222>  (2)..(13)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  15

Xaa Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg 
1               5                   10              


<210>  16
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCPP5


<220>
<221>  VARIANT
<222>  (2)..(14)
<223>  Wherein  Arg is L-Arg or homoArg.

<220>
<221>  VARIANT
<222>  (4)..(16)
<223>  Wherein Xaa is  -NH-(CH2)5C(O)-

<400>  16

Lys Arg Lys Xaa Lys Arg Lys Xaa Lys Arg Lys Xaa Lys Arg Lys Xaa 
1               5                   10                  15      


Asx 
    


<210>  17
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCPP6

<400>  17

Lys Phe Lys Lys Phe Lys Lys Phe Lys Lys Phe Lys Lys Phe Lys 
1               5                   10                  15  


<210>  18
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCPP7


<220>
<221>  VARIANT
<222>  (1)..(12)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  18

Arg Leu Leu Phe Arg Lys Ile Arg Arg Leu Lys Arg 
1               5                   10          


<210>  19
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCPP8


<220>
<221>  VARIANT
<222>  (1)..(20)
<223>  Wherein  Arg is L-Arg or homoArg.

<400>  19

Arg Arg Leu Ala Arg Arg Ile Leu Arg Ala Leu Arg Ala Arg Phe Arg 
1               5                   10                  15      


Ala Phe Arg Arg 
            20  


<210>  20
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PPNA 23X

<400>  20
gccatcagcc gtgct                                                        15


<210>  21
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PPNA 24X

<400>  21
gacgctcatt tgcta                                                        15


<210>  22
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PPNA 25X

<400>  22
ctacttccat cttcc                                                        15


<210>  23
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PPNA 23X

<400>  23
gccatcagcc gtgct                                                        15


<210>  24
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PPNA 40

<400>  24
ctttacgcat gagag                                                        15


<210>  25
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PPNA 39

<400>  25
ttgccactct tgcac                                                        15


<210>  26
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PPNA 38

<400>  26
tagttgccat gtctc                                                        15


<210>  27
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PPNA 36

<400>  27
gctccaaatt ccgac                                                        15


<210>  28
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PEG6


<220>
<221>  variant
<222>  (1)..(13)
<223>  Wherein Arg is Homo-Arg

<220>
<221>  variant
<222>  (1)..(13)
<223>  Wherein Xaa is 6-amino-hexanoic Acid

<400>  28

Xaa Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg 
1               5                   10              


<210>  29
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PPNA 40-PEG3


<220>
<221>  Variant
<222>  (8)..(8)
<223>  Wherein Xaa is Beta- Alanine

<220>
<221>  Variant
<222>  (9)..(20)
<223>  Wherein Xaa is 6-amino-hexanoic Acid

<400>  29

Ala Glu Glu Ala Ala Glu Ala Xaa Arg Xaa Arg Arg Xaa Arg Arg Xaa 
1               5                   10                  15      


Arg Arg Xaa Arg 
            20  


